Immuno Cure focuses on R&D of immunotherapies for cancers, inflammatory and infectious diseases
The Hong Kong Science Park-based biotech company will use the new money to speed up the development of DNA vaccines and antibodies and get ready for a local initial public offering (IPO).
- Funding amount: US$12,000,000
- Lead investor: AEF Greater Bay Area Fund
- Stage: Series A
Immuno Cure was started in 2015, and it focuses on cancer immunotherapies as well as immunotherapies for illnesses that cause inflammation and infections. Immunotherapy is a medicine that uses the body’s immune system to find and kill cancer cells.
The company is currently testing ICVAX and ICCOV, which are both potential DNA vaccines.
Immuno Cure’s CEO, Xia Jin, said that the company will keep working on research and development for new vaccine technologies “to improve our arsenal against cancers and infectious diseases.”
Also Read: Twitter Rebranding
The Hong Kong Science and Technology Parks Corporation gave the company a grant of $910,000 in June so that it could start a clinical study with the University of Hong Kong. The goal of the study is to find out how well a booster DNA vaccine against Covid-19 works.
Immuno Cure BioTech
|AEF Greater Bay Area Fund